Use the filters below to refine your results
Pre-clinical | |
Phase One | |
Phase Two | |
Phase Three | |
Available to Patients |
Binding gluten so it’s not absorbed | ||
Breaking down gluten using enzymes | ||
Interrupting the immediate or delayed effects of gluten on the cells lining the intestine | ||
Preventing the enzyme tTG from modifying gluten in the cell | ||
Inducing immune tolerance to protect against the effects of gluten by preventing an immune reaction | ||
Interrupting the immune reactions that occur |
Active | |
Discontinued |
Did you know that researchers are currently developing drugs to treat celiac disease? One day, our community may have a pill to defend against cross-contact, an injection to prevent the immune system from attacking the small intestine, or even a treatment to replace the gluten-free diet entirely.
If that sounds exciting to you, be sure to bookmark this page and subscribe to our research newsletter, where we update you with any changes to the celiac disease drug development scene.
The process of developing a treatment and getting it to market is long and fraught with challenges. About 90% of all drugs in clinical trials never make it to market (although it’s closer to 85% for autoimmune conditions specifically!). But we firmly believe that it’s only a matter of time before our community has a treatment beyond the gluten-free diet. Learn how we’re accelerating the process. And to learn about the phases of drug development, download our Clinical Trials infographic.
Last updated 5/29/25
Opt-in to stay up-to-date on the latest news.
Yes, I want to advance research No, I'd prefer not to